EAErik Andrade-Jorge

Erik Andrade-Jorge

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Erik Andrade-Jorge has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • José Guadalupe Trujillo Ferrara

    Laboratorio de Bioquímica, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Diaz Mirón s/n, Col. Casco de Santo Tomas, Alc. Miguel Hidalgo, Mexico City 11340, Mexico

    7 shared publications
  • Marvin Antonio Soriano Ursúa

    Academia de Fisiología y Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina del Instituto Politécnico Nacional, Plan de San Luis y Diaz Mirón s/n., Alc. Miguel Hidalgo, Mexico City 11340, Mexico

    3 shared publications
  • Ricardo Tovar-Miranda

    Instituto de Ciencias Básicas, Universidad Veracruzana, Apartado Postal 575, Xalapa, Ver., 91000 México, and Departamento de Química del Centro de Investigación y de Estudios Avanzados, Instituto Politécnico Nacional, Apartado 14-740, México, D.F., 07000 México

    3 shared publications
  • Héctor Luna

    Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana, Unidad Xochimilco, Ciudad de México C.P. 04690, Mexico

    2 shared publications
  • Itzia I. Padilla-Martínez

    Laboratorio de Química Supramolecular y Nanociencias, Unidad Profesional Interdisciplinaria de Biotecnología, Instituto Politécnico Nacional, Avenida Acueducto s/n, Barrio la Laguna Ticomán, Mexico City 07340, Mexico

    2 shared publications
  • Luis A. Sánchez-Labastida

    Departamentos de Bioquímica y Fisiología, Escuela Superior de Medicina-Instituto Politécnico Nacional, Miguel Hidalgo, Mexico

    2 shared publications

Latest Publications

  • Open Access

    Preclinical Evaluation of 2-Aminobenzothiazole Derivatives: In Silico, In Vitro, and Preliminary In Vivo Studies as Diabetic Treatments and Their Complications

    by Natalia Reyes-Vallejo, Miguel Valdes, Adelfo Reyes-Ramírez, Juan Andres Alvarado-Salazar, Alejandro Cruz, Erik Andrade-Jorge, Jessica Elena Mendieta-Wejebe

    Type 2 diabetes is a multifactorial disease characterized by chronic hyperglycemia, insulin resistance, oxidative stress, inflammation, and dyslipidemia, factors that contribute to the development of long-term complications. In this context, the 2-aminobenzothiazole scaffold has emerged as a promising candidate due to its broad spectrum of biological properties. In this study, we performed a multidisciplinary evaluation of benzothiazole derivatives (5a–d, 8a–d, 11a–d, and 12c–d), starting with the in silico prediction of their properties, along with molecular docking against aldose reductase (ALR2) and peroxisome proliferator-activated receptor gamma (PPAR-γ). All compounds complied with the main rules of pharmacological similarity and optimal affinity, highlighting 8d (ΔG = −8.39 kcal/mol for ALR2 and −7.77 kcal/mol for PPAR-γ). Selected compounds from families C and D were synthesized in moderate yields (~60%) and showed low acute oral toxicity (LD50 > 1250 mg/Kg). Compounds 8c and 8d inhibited ALR2 at concentrations below 10 µM. In vivo studies using a streptozotocin-induced diabetic rat model with a high-fat diet revealed that compound 8d produced sustained antihyperglycemic effects and reduced insulin resistance, dyslipidemia, and polydipsia, without inducing hepatotoxicity or displaying intrinsic antioxidant or anti-inflammatory activity. These findings suggest that 8d is a promising candidate for further development in diabetes-related therapeutic strategies.


  • Benzofurans as Acetylcholinesterase Inhibitors for Treating Alzheimer's Disease: Synthesis, in vitro Testing, and in silico Analysis

    by Arturo Coaviche‐Yoval, Ricardo Tovar‐Miranda, Jessica E. Rodríguez, Jesus A. Lagos‐Cruz, Héctor Luna, Erik Andrade‐Jorge, José G. Trujillo‐Ferrara

    Alzheimer's disease (AD) is a neurodegenerative disorder and the leading cause of dementia worldwide. It is characterized by a progressive decline in cholinergic neurotransmission. During the development of AD, acetylcholinesterase (AChE) binds to β‐amyloid peptides to form amyloid fibrils, which aggregate into plaque deposits. Meanwhile, tau proteins are hyperphosphorylated, forming neurofibrillary tangles (NFTs) that aggregate into inclusions. These complexes are cytotoxic for the brain, causing impairment of memory, attention, and cognition. AChE inhibitors are the main treatment for AD, but their effect is only palliative. This study aimed to design and synthesize novel benzofuran derivatives and evaluate their inhibition of AChE in vitro and in silico. Results: The seven synthesized benzofuran derivatives inhibited AChE in vitro. Benzofurans hydroxy ester 4, amino ester 5, and amido ester (±)‐7 had the lowest inhibition constant (Ki) values and displayed good affinity for EeAChE in molecular docking. Six derivatives showed competitive inhibition, while the best compound (5: Ki=36.53 μM) exhibited uncompetitive inhibition. The amino, hydroxyl, amide, and ester groups of the ligands favored interaction with the enzyme by hydrogen bonds. Conclusion: Three benzofurans were promising AChE inhibitors with excellent Ki values. In future research on their their application to AD, 5 will be considered as the base structure.


  • In silico and in vivo neuropharmacological evaluation of two γ-amino acid isomers derived from 2,3-disubstituted benzofurans, as ligands of GluN1–GluN2A NMDA receptor

    by Arturo Coaviche-Yoval, José G. Trujillo-Ferrara, Marvin A. Soriano-Ursúa, Erik Andrade-Jorge, Luis A. Sánchez-Labastida, Héctor Luna, Ricardo Tovar-Miranda

    The GABAergic and glutamatergic neurotransmission systems are involved in seizures and other disorders of the central nervous system (CNS). Benzofuran derivatives often serve as the core in drugs used to treat such neurological disorders. The aim of this study was to synthesize new γ-amino acids structurally related to GABA and derived from 2,3-disubstituted benzofurans, analyze in silico their potential toxicity, ADME properties, and affinity for the GluN1–GluN2A NMDA receptor, and evaluate their potential activity and neuronal mechanisms in a murine model of pentylenetetrazol (PTZ)- and 4-aminopyridine (4-AP)-induced seizures. The in silico analysis evidenced a low risk of toxicity for the test compounds as well as the probability that they can cross the blood–brain barrier (BBB) to reach their targets in the CNS. According to docking simulations, these compounds bind at the active site of the NMDA glutamate receptor with high affinity. The in vivo assays demonstrated that 4 protects against 4-AP-induced seizure episodes, suggesting negative allosteric modulation (NAMs) at the glutamatergic NMDA receptor. Contrarily, 3 (the regioisomer of 4) and its racemic derivatives (cis-2,3-dihydrobenzofurans) were previously described to exacerbate such episodes, pointing to their positive allosteric modulation (PAMs) of the same receptor.


  • Acetylcholinesterase Inhibition (Potential Anti‐Alzheimer Effects) by Aminobenzoic Acid Derivatives: Synthesis, in Vitro and in Silico Evaluation

    by José A. Altamirano‐Espino, Luis A. Sánchez‐Labastida, Marlet Martínez‐Archundia, Erik Andrade‐Jorge, José G. Trujillo‐Ferrara

    Alzheimer's disease is a neurodegenerative condition that decreases cognitive function. Thus, intense research efforts have focused on developing acetylcholinesterase (AChE) inhibitors with less side effects. The aim of this study was to synthesize aminobenzoic acid derivatives and test their AChE inhibitory capacity in silico and in vitro. Ten electron‐poor aminobenzoic acid derivatives were synthesized in good‐high yields. Their interaction with EeAChE, according to docking simulations, is mainly mediated by the aromatic ring of the ligands and the catalytic triad of the receptor (π‐π interactions). The in vitro evaluation revealed mixed inhibition (mostly competitive) in all cases. The structural analysis showed better Ki values for heterocyclic than linear compounds and with the presence of two carboxylic groups attached. 5‐Aminoisophthalic acid (AIPA_3, K I =73 μM) showed the lowest K I of all compounds. The electron‐poor aromatic ring of the test compounds is recognized by the electron‐rich peripheric and catalytic binding sites of AChE. AIPA_3, with the best properties, is a promising lead compound for developing new AChE inhibitors.


  • Inhibitory activity on cholinesterases produced by aryl-phthalimide derivatives: green synthesis, in silico and in vitro evaluation

    by Omar Ruiz-Maciel, Itzia I. Padilla-Martínez, Luis A. Sánchez-Labastida, Marvin A. Soriano-Ursúa, Erik Andrade-Jorge, José G. Trujillo-Ferrara


  • Identification of two arylimides as cholinesterase inhibitors and testing of propranolol addition on impaired rat memory

    by Fabiola J. Ciprés‐Flores, Eunice D. Farfán‐García, Erik Andrade‐Jorge, Roberto I. Cuevas‐Hernández, Feliciano Tamay‐Cach, Marlet Martínez‐Archundia, José G. Trujillo‐Ferrara, Marvin A. Soriano‐Ursúa

    Alzheimer's disease (AD) is clearly linked to the decline of acetylcholine (ACh) effects in the brain. These effects are regulated by the hydrolytic action of acetylcholinesterase (AChE). Therefore, a central palliative treatment of AD is the administration of AChE inhibitors although additional mechanisms are currently described and tested for generating advantageous therapeutic strategies. In this work, we tested new arylamides and arylimides as potential inhibitors of AChE using in silico tools. Then, these compounds were tested in vitro, and two selected compounds, C7 and C8, as well as propranolol showed inhibition of AChE. In addition, they demonstrated an advantageous acute toxicity profile compared to that of galantamine as a reference AChE inhibitor. in vivo evaluation of memory performance enhancement was performed in an animal model of cognitive disturbance with each of these compounds and propranolol individually as well as each compound combined with propranolol. Memory improvement was observed in each case, but without a significant additive effect with the combinations.


  • Open Access

    Quantum Reality in the Selective Reduction of a Benzofuran System

    by Arturo Coaviche-Yoval, Erik Andrade-Jorge, Cuauhtémoc Pérez-González, Héctor Luna, Ricardo Tovar-Miranda, José G. Trujillo-Ferrara

    Two 2,3-disubstituted benzofurans (1 and 2), analogs of gamma-aminobutyric acid (GABA), were synthesized to obtain their 2,3-dihydro derivatives from the Pd/C-driven catalytic reduction of the double bond in the furanoid ring. The synthesis produced surprising by-products. Therefore, theoretical calculations of global and local reactivity were performed based on Pearson’s hard and soft acids and bases (HSAB) principle to understand the regioselectivity that occurred in the reduction of the olefinic carbons of the compounds. Local electrophilicity (ωk) was the most useful parameter for explaining the selectivity of the polar reactions. This local parameter was defined with the condensed Fukui function and redefined with the electrophilic (Pk+) Parr function. The similar patterns of both resulting sets of values helped to demonstrate the electrophilic behavior (soft acid) of the olefinic carbons in these compounds. The theoretical calculations, nuclear magnetic resonance, and resonance hybrids showed the moieties in each compound that are most susceptible to reduction.


  • Open Access

    Crystal structure, DFT calculations and evaluation of 2-(2-(3,4-dimethoxyphenyl)ethyl)isoindoline-1,3-dione as AChE inhibitor

    by Erik Andrade-Jorge, José Bribiesca-Carlos, Francisco J. Martínez-Martínez, Marvin A. Soriano-Ursúa, Itzia I. Padilla-Martínez, José G. Trujillo-Ferrara

    Dioxoisoindolines have been included as a pharmacophore group in diverse drug-like molecules with a wide range of biological activity. Various reports have shown that phthalimide derivatives are potent inhibitors of AChE, a key enzyme involved in the deterioration of the cholinergic system during the development of Alzheimer’s disease. In the present study, 2-(2-(3,4-dimethoxyphenyl)ethyl)isoindoline-1,3-dione was synthesized, crystallized and evaluated as an AChE inhibitor. The geometric structure of the crystal and the theoretical compound (from molecular modeling) were analyzed and compared, finding a close correlation. The formation of the C6–H6···O19 interaction could be responsible for the non-negligible out of phenyl plane deviation of the C19 methoxy group, the O3 from the carbonyl group lead to C16–H16···O3i intermolecular interactions to furnish C(9) and C(14) infinite chains within the (− 4 0 9) and (− 3 1 1) families of planes. Finally, the biological experiments reveal that the isoindoline-1,3-dione exerts a good competitive inhibition on AChE (Ki = 0.33–0.93 mM; 95% confidence interval) and has very low acute toxicity (LD50 > 1600 mg/kg) compared to the AChE inhibitors currently approved for clinical use.